Mantle David, Hargreaves Iain Parry
Pharma Nord (UK) Ltd., Morpeth, Northumberland NE61 2DB, UK.
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Merseyside L3 5UX, UK.
Antioxidants (Basel). 2024 Apr 26;13(5):530. doi: 10.3390/antiox13050530.
To date, there have been no review articles specifically relating to the general efficacy and safety of coenzyme Q10 (CoQ10) supplementation in younger subjects. In this article, we therefore reviewed the efficacy and safety of CoQ10 supplementation in neonates (less than 1 month of age), infants (up to 1 year of age) and children (up to 12 years of age). As there is no rationale for the supplementation of CoQ10 in normal younger subjects (as there is in otherwise healthy older subjects), all of the articles in the medical literature reviewed in the present article therefore refer to the supplementation of CoQ10 in younger subjects with a variety of clinical disorders; these include primary CoQ10 deficiency, acyl CoA dehydrogenase deficiency, Duchenne muscular dystrophy, migraine, Down syndrome, ADHD, idiopathic cardiomyopathy and Friedreich's ataxia.
迄今为止,尚无专门针对辅酶Q10(CoQ10)补充剂在较年轻人群中的总体疗效和安全性的综述文章。因此,在本文中,我们回顾了CoQ10补充剂在新生儿(小于1月龄)、婴儿(1岁以下)和儿童(12岁以下)中的疗效和安全性。由于在正常较年轻人群中(与健康老年人群不同)没有补充CoQ10的理论依据,因此本文综述的医学文献中的所有文章均涉及CoQ10在患有各种临床疾病的较年轻人群中的补充;这些疾病包括原发性CoQ10缺乏症、酰基辅酶A脱氢酶缺乏症、杜氏肌营养不良症、偏头痛、唐氏综合征、注意力缺陷多动障碍、特发性心肌病和弗里德赖希共济失调。